Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose atorvastatin versus high-dose rosuvastatin for lipid profile improvement in STEMI patients after primary PCI
IRCT20191217045767N1Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Dec 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of atorvastatin and rosuvastatin in acute ST-segment elevation myocardial infarction (STEMI) and hyperlipidemia (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoint: Effectiveness of high dose statin therapy on lipid profile in STEMI patients and comparison of the effect of high-dose atorvastatin and high-dose rosuvastatin. Started Dec 2019; status: completed.
02
Drugs
atorvastatinrosuvastatin
03
Conditions
acute ST-segment elevation myocardial infarction (STEMI)hyperlipidemia
Beyond the preview
Go deeper on IRCT20191217045767N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191217045767N1.